Innovate UK

StimOxyGen is a biotechnology company focused on developing innovative, pH-responsive nanoparticles. These nanoparticles are designed to generate oxygen in hypoxic (low oxygen) tumors, enhancing the effectiveness of cancer treatments like radiotherapy and chemotherapy. The company's core technology involves a nanoparticle formulation that dissolves in the low pH environment of tumors, transiently producing oxygen and thereby maximizing the therapeutic effects of radiotherapy.

Constructive Bio is a biotechnology company focused on genome rewriting to advance bioprocesses and biopharmaceuticals. By transforming living cells into biofactories, it aims to develop sustainable materials and therapeutics. The company possesses the capability to create virus-resistant organisms and utilizes its proprietary technology to biosynthesize various classes of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram the genetic code, enabling the production of natural molecules and exploring chemical spaces that are not accessible through traditional biological methods. Constructive Bio's work positions it at the forefront of biotechnology, paving the way for the next generation of sustainable solutions in the life sciences sector.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Circadacare is a health technology company focused on enhancing the quality of life for older adults in care environments. By leveraging scientific principles, the company offers innovative lighting solutions that synchronize with the natural day-night cycle, improving the well-being of residents while also benefiting staff. Their integrated system combines lighting, sensors, and software technology to create an optimal care setting that fosters mood and engagement. Circadacare aims to simplify operations for care providers, ensuring that their systems function seamlessly without requiring extensive training or intervention from staff. This approach not only enhances care outcomes for residents but also offers cost benefits to operators of nursing homes, care villages, and dementia care centers.

Axial3D specializes in 3D printing for healthcare, focusing on creating precise, patient-specific physical models derived from CT and MRI scans. Their online ordering portal enables secure uploads, with an expert team using advanced technology to deliver these models directly to consultants. The company aims to enhance surgical planning, technique development, and ultimately improve patient outcomes by integrating 3D printing into mainstream medical practice.

MediMusic is a developer of a medical technology platform that harnesses the power of soothing music to assist patients in managing pain, anxiety, and stress. The company employs artificial intelligence to curate personalized playlists that not only lower heart rates but also stimulate the vagus nerve, promoting a favorable physio-endocrine response. This innovative approach aims to help individuals reduce stress and anxiety while enhancing the efficacy of pain medication, thereby contributing to overall well-being. MediMusic focuses on improving patient care through its unique blend of health technology and music therapy, targeting conditions such as dementia and anxiety.

Dia Beta Labs is a biotechnology company dedicated to improving the lives of individuals with metabolic diseases. It operates from Ulster, where it has access to advanced facilities and a network of experts. The company's focus is on developing therapeutic agents to address the decline of pancreatic health in patients, with the goal of achieving more sustainable and effective weight loss than current options. Its discovery platform uses industry-standard methodologies and models to identify and advance lead molecules for animal research.

ChromaTwist is a developer of innovative ultraviolet fluorescent dyes designed for applications in bio-sensing and bio-imaging diagnostic tests. The company's proprietary technology platform utilizes shifted organic fluorescent dyes, which emit visible light upon UV irradiation. These dyes are composed of aromatic organic materials featuring donor and acceptor groups, allowing them to absorb UV light and emit across the full visible spectrum. ChromaTwist's modular and scalable chemistry enables the continuous advancement of their fluorophores, thereby expanding their potential applications in the healthcare sector, particularly in areas like flow cytometry and multiphoton microscopy.

Epitopea is a transatlantic biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a novel class of tumor-specific antigens. The company utilizes a proprietary technique that integrates immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's genetic material. This approach, developed through research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal, aims to create therapies that selectively eliminate malignant cells while preserving healthy tissue. By targeting antigens that are broadly shared among patients with the same cancer type, Epitopea seeks to enhance treatment efficacy while minimizing side effects and providing durable benefits.

ScubaTx is a company focused on developing an advanced organ preservation system that utilizes the Persufflation method, a well-established technique aimed at enhancing organ transportation. By leveraging innovative software design, ScubaTx aims to provide significant cost savings for healthcare providers, thereby facilitating an expanded supply of viable organs for transplantation. The company’s technology is designed to protect and improve the condition of grafts during the preservation process, ultimately empowering clinicians worldwide to increase the availability of life-saving organs.

Mestag Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases through its unique fibroblast technology. The company leverages emerging insights into the role of activated fibroblast populations in disease progression to create therapeutics that disrupt fibroblast-mediated effects on immune cells. By targeting these mechanisms, Mestag aims to enhance treatment options and improve outcomes for patients suffering from rare and life-threatening conditions.

Lentitek is a cell and gene therapy company focused on developing innovative treatments for cancer patients. The company is dedicated to making advanced therapeutics more accessible by enhancing the production of lentiviral vectors, which are essential for gene therapies. Lentitek employs a proprietary method that utilizes a novel promoter and a triple transfection production process to significantly increase viral yields by tenfold or more. This approach not only improves the efficiency of lentiviral production but also aims to lower production costs for healthcare providers, thereby broadening the availability of its therapies to a larger patient population.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

Siloton is a medical device manufacturing company specializing in the design and development of diagnostic imaging devices for ophthalmology. The company focuses on creating portable optical coherence tomography devices aimed at addressing challenges within this field. Notably, Siloton develops advanced hand-held sub-surface imaging devices that enable clients to use a home-based scanning module, contributing to the prevention of blindness.

BoobyBiome is a company focused on enhancing infant health through the development of probiotic supplements specifically designed for babies with compromised microbiomes. By leveraging specialized expertise and research, BoobyBiome aims to recreate the beneficial bacteria associated with breast milk, particularly for infants born prematurely or those who rely on formula feeding. Their products are formulated to closely mimic the properties of breast milk, providing essential support for gut health and immune system development in infants. Through these innovative probiotic solutions, BoobyBiome seeks to promote healthy growth and development during a critical stage of life.

Awen Oncology is a pre-clinical stage pharmaceutical company focused on developing novel cancer therapies. It specializes in targeting 'developmentally-silent oncogenic drivers', which are genes that contribute to cancer growth but are not typically targeted by existing treatments. The company's approach combines expertise in cell and molecular biology with advanced structural biology and in-silico drug screening to rapidly and efficiently identify and develop effective cancer treatments.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, that focuses on developing innovative treatments for patients with autoimmune diseases and cancers. Founded in 2009, the company is dedicated to creating first-in-class antibody therapies, particularly its lead product, annexuzlimab, a monoclonal antibody designed to target and inhibit annexin-A1. This approach aims to modulate both the innate and adaptive immune systems, thereby enhancing treatment options for healthcare providers and improving patient outcomes. Through its specialized research and development efforts, MedAnnex seeks to address significant unmet medical needs in the field of immunotherapy.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

ThirtyFiveBio is a biotechnology company focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, an area marked by significant unmet clinical needs. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify contemporary small-molecule modulators of specific proteins, particularly targeting GPR35 signaling pathways. By addressing the challenges associated with digestive system malignancies, ThirtyFiveBio aims to offer therapeutic solutions that could help prevent tumor growth and improve patient outcomes.

BiVictriX Therapeutics Ltd. is a drug discovery and development company based in Alderley Edge, United Kingdom, focused on creating bispecific antibody drug conjugates to address unmet medical needs in blood cancer. Established in 2016, the company leverages its proprietary Bi-Cygni technology to develop innovative therapies for various types of cancers, including Acute Myeloid Leukaemia. BiVictriX specializes in oncology and haematological malignancies, offering a range of services that encompass biotherapeutics, immunotherapy, antibody research, and drug development. The company aims to advance its pharmaceutical products through rigorous development processes to improve treatment outcomes for patients with serious medical conditions.

Nuclera is a biotechnology company specializing in an automated protein prototyping system aimed at enhancing drug discovery processes. Its eProtein Discovery system enables researchers to rapidly produce and test high-quality, soluble, and active proteins, significantly accelerating protein projects. By integrating technology such as cell-free protein synthesis and digital microfluidics, Nuclera provides a high-throughput platform for automated protein access. This innovative approach allows scientists to obtain reliable proteins within a short timeframe, facilitating faster progress in their research and contributing to more efficient drug development efforts.

Fuse Diagnostics is a company dedicated to providing lab-quality diagnostic information through innovative and cost-effective testing solutions. The company manufactures diagnostic products designed to deliver accurate results for various applications, including food and water testing, bioprocessing industry needs, and cell biology research. Fuse Diagnostics aims to make high-quality diagnostic information accessible wherever it is needed, offering low-cost test kits with integrated readout technology that provide rapid results.

LIfT BioSciences is a biotechnology company based in London, established in 2016, that specializes in advanced innate immuno-cell therapies. It has developed a unique platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT), which enables the production of Immunomodulatory Alpha Neutrophils (IMANs) from induced pluripotent stem cells (iPSCs). This technology aims to address the limitations of existing therapies for solid tumors by utilizing CAR neutrophil cell therapy. The IMANs can alter the tumor microenvironment, enhancing the immune response and enabling a more effective attack on tumors. By leveraging proprietary enhancement media and genetic engineering, LIfT BioSciences seeks to significantly increase the cancer-fighting capabilities of these cells, offering patients the potential for improved outcomes and lasting immunity against cancer.

The University of Bristol is a red brick research university that offers a range of educational courses and services. The university is organized into six academic facilities: Faculty of Arts, Faculty of Engineering, Faculty of Medical and Veterinary Sciences, Faculty of Science, Faculty of Medicine and Dentistry, and Faculty of Social Sciences and Law. These faculties together award a range of academic degrees spanning bachelor's and master's degrees as well as junior doctorates and higher doctorates. University of Bristol was established in 1876 and is based in Bristol, United Kingdom.

Monument Therapeutics is a biotechnology company focused on developing innovative drugs for serious diseases affecting the central nervous system. The company employs proprietary digital biomarkers to reduce variability in patient populations and identify individuals with similar underlying neurobiology. This targeted approach aims to enhance the research and development of neuroscience drugs in areas with significant unmet medical needs, ultimately advancing treatment options for these complex conditions.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

Presymptom Health is a medical technology company dedicated to advancing healthcare through the development of pre-symptomatic diagnostic tests and clinical decision support algorithms. The company focuses on creating innovative blood tests designed to detect illnesses at an early stage, particularly aiming to predict the onset of sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health seeks to improve critical care outcomes and enhance patient management, ultimately contributing to better survival rates and healthcare efficiency.

Cortirio is a developer of portable brain imaging technology aimed at improving the diagnosis and treatment of traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company designs portable scanners that utilize near-infrared imaging to deliver high-resolution, point-of-care medical imaging. These wearable devices provide critical information throughout the clinical pathway, facilitating automatic analysis and efficient data transfer. By equipping clinicians with rapid and accurate diagnostic tools, Cortirio enhances decision-making processes and improves care for patients suffering from brain injuries and strokes, ultimately aiming to reduce treatment times and prevent long-term disability or death.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on advancing treatment options for patients with chronic wounds. Founded in 2017, the company is developing Aurase, a hydrogel designed to enhance wound bed preparation through the application of a recombinant enzyme derived from maggots. This innovative approach aims to facilitate wound debridement, a crucial therapeutic procedure that removes dead, damaged, or infected tissue, thereby accelerating the healing process. By leveraging biomimicry and evidence-based medicine, SolasCure seeks to improve patient outcomes across various healthcare settings.

IXICO plc, established in 1995 and headquartered in London, specializes in providing data analytics services to the global biopharmaceutical industry. The company focuses on the collection, analysis, management, and reporting of data generated during clinical studies, with a particular emphasis on neurological diseases. IXICO's key technologies include Assessa, a digital platform for clinical decision support, and TrialTracker, a comprehensive imaging service workflow management system. The company's end-to-end imaging services are primarily applied in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases. IXICO's services are utilized to select patients for clinical trials, assess drug safety and efficacy, and for post-marketing surveillance. The company works with pharmaceutical companies, biotech firms, academia, and medical charities worldwide.

Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.

Aelius Biotech specializes in developing advanced models of the mucosal surfaces of the human body, including the gastrointestinal tract and airways. The company is actively working on creating model systems for the eye and cervico-vaginal tract. Aelius Biotech provides a comprehensive range of in vitro and in vivo testing services, including simple lab assays, routine testing, and rheology. Their integrated model gut system allows healthcare industry participants to simulate key processes such as digestion, mucus permeation, and epithelial absorption in one cohesive platform. By conducting human trials and offering detailed insights, Aelius Biotech aids healthcare companies in making informed, data-driven decisions to enhance and de-risk the development of orally delivered products.

AMPLY Discovery is a biotechnology company focused on drug discovery, utilizing machine learning and synthetic biology to explore vast biological datasets for novel drug and nutraceutical candidates. The company operates a proprietary platform that integrates in silico and in vitro approaches to identify first-in-class molecules, addressing significant health challenges such as cancer, metabolic diseases, and multidrug-resistant infections. By digitizing life's natural diversity, AMPLY enhances the predictability and cost-effectiveness of discovering new therapeutics, enabling research entities to identify promising drug candidates based on their functional properties.

Lucida Medical is a healthcare technology company focused on developing artificial intelligence solutions to enhance the detection and diagnosis of cancer. The company’s flagship product, Pi, is a CE marked medical device that utilizes multiparametric and diffusion MRI to support prostate cancer diagnosis. By leveraging advanced imaging and multi-omics biomarkers, Lucida Medical aims to provide clinicians with accurate, accessible, and cost-effective tools for cancer screening and management. Their innovative technology is designed to improve the efficiency of cancer detection, ultimately enabling healthcare professionals to make timely and informed decisions regarding patient care.

Mesenbio is a preclinical biopharmaceutical company based at the University of York, specializing in cell-derived therapies. It has developed a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which aims to enhance the treatment pipeline by addressing significant challenges in extracellular vesicle therapy. The company focuses on creating innovative treatments, including a novel therapy for arthritis derived from engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio seeks to transform medical approaches to musculoskeletal diseases, thereby providing more effective therapeutic options.

The University of Edinburgh, established in 1583, is a prestigious institution located in Edinburgh, United Kingdom. It is renowned globally for its academic excellence, offering a wide range of disciplines, including its renowned Medical School and Law School. As one of Scotland's ancient universities, it is committed to delivering high-quality education, conducting cutting-edge research, and fostering innovation to address global challenges.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

CellRev is a biotechnology company that specializes in advancing cell manufacturing processes through innovative bioprocessing technology. The company focuses on enabling the transition from traditional batch processing to continuous processing for adherent cells, which enhances yield and reduces both operating costs and capital expenditure. By addressing critical challenges such as aggregation, clumping, and cell detachment, CellRev offers unique solutions for developers in the fields of cultured meat, cell therapy, and biologics. Its proprietary cell detachment process, combined with a specially designed bioprocess, positions CellRev as a leader in improving the efficiency of manufacturing processes for cell-based vaccines, therapies, and drugs. This disruptive approach aims to eliminate the need for serum in production, thereby streamlining operations for clients in the biomanufacturing landscape.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

Spirecut is a MedTech company that specializes in developing patented surgical instruments for treating hand conditions, specifically carpal tunnel syndrome and trigger finger. The company's innovative approach utilizes ultrasound-guided surgery, eliminating the need for skin incisions and resulting in no post-operative wounds. This advancement allows patients to resume their daily activities without the necessity of dressing or covering the operated area. Spirecut's instruments represent a significant improvement over traditional needles, facilitating the safe release of thickened tissue and enhancing preoperative sonographic tracking. By optimizing surgical outcomes, Spirecut aims to elevate the standard of care in hand surgery and accelerate patient recovery.

Physiomics Plc is a consulting firm based in Oxford, United Kingdom, specializing in services for pharmaceutical companies in the realms of quantitative pharmacology and computational biology. Established in 2001, the company utilizes its proprietary Virtual Tumour predictive software to offer modeling, simulation, and data analysis services, primarily focused on oncology research and development. By combining systems biology with advanced mathematical techniques, Physiomics aims to optimize dosing and scheduling of oncology drugs during pre-clinical and clinical trials, enhancing the efficacy of drug combinations and streamlining the overall drug development process. The company's operations extend across the United Kingdom, the European Union, Switzerland, and the United States, with a commitment to advancing personalized medicine through innovative technology.

Laverock Therapeutics is focused on advancing a gene silencing platform that facilitates the development of programmable, allogeneic cell therapies. This innovative platform allows for the engineering of next-generation cell therapies that are both adaptive and capable of responding to various intra- and extra-cellular environmental cues. By enhancing the functionality of these therapies, Laverock Therapeutics aims to improve the efficacy, safety, and accessibility of iPSC-derived products, addressing significant limitations associated with current therapeutic approaches. The company's work is positioned to benefit medical and biotechnology institutions seeking to leverage advanced cell therapy solutions.

Brainomix Limited is a medical technology company based in Oxford, United Kingdom, that specializes in developing imaging biomarkers and software solutions for neurological and cerebrovascular disorders. Founded in 2010 as a spin-out from the University of Oxford, Brainomix focuses on enhancing clinical decision-making through its AI-powered products. Its flagship offering, e-Stroke, comprises a suite of tools that provide real-time interpretation of brain scans, enabling healthcare professionals to make informed treatment decisions for stroke patients more efficiently. This includes e-ASPECTS, which automates the scoring of brain images to identify early stroke damage, and e-CTA, which standardizes the detection of large vessel occlusions. Additionally, e-Mismatch provides a multi-vendor post-processing solution for MRI and CT scans, enhancing the assessment of stroke damage. By leveraging advanced algorithms and large data analytics, Brainomix aims to improve patient outcomes by ensuring timely and appropriate treatment for stroke patients worldwide.

ThirtyFiveBio is a biotechnology company focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, an area marked by significant unmet clinical needs. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify contemporary small-molecule modulators of specific proteins, particularly targeting GPR35 signaling pathways. By addressing the challenges associated with digestive system malignancies, ThirtyFiveBio aims to offer therapeutic solutions that could help prevent tumor growth and improve patient outcomes.

Stablepharma Ltd is a biotechnology company based in Bath, United Kingdom, focused on developing innovative processes for vaccine stabilization. Its technology platform, StablevaX™, transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration, addressing significant challenges in cold chain logistics. By enabling pre-dosed and stable vaccine delivery, Stablepharma aims to eliminate waste and reduce costs in the distribution of medical products. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates actively with global vaccine manufacturers, academic institutions, and non-governmental organizations to advance its pipeline of thermostable solutions. Established in 2012, Stablepharma is dedicated to improving access to vaccines for children and adults, while also contributing to reduced carbon dioxide emissions in the healthcare sector.

Jude is a healthcare company focused on addressing bladder-related issues and raising awareness about incontinence. It provides a range of bladder care solutions, including access to medical specialists who offer advice through social media platforms, virtual workshops, and private chat sessions. In addition to educational resources, Jude supplies health products designed to help individuals understand their conditions and manage them effectively. By promoting open discussions and providing expert guidance, Jude aims to empower individuals to lead leak-free lives and break the stigma surrounding bladder health.

AstronauTx is a biotechnology company focused on developing innovative treatments for Alzheimer's disease and other neurodegenerative conditions. The company specializes in restoring the normal function of astrocytes, which are crucial for supporting neuronal activity and maintaining brain health. In healthy individuals, astrocytes play a vital role in metabolism and the integrity of the blood-brain barrier; however, in neurodegenerative diseases, their dysfunction can contribute to neurotoxicity. By targeting these processes, AstronauTx aims to enable healthcare professionals to more effectively address the challenges posed by dementias, ultimately improving patient outcomes.

Plasticell is a biotechnology company focused on developing innovative therapeutic solutions through advanced cell culture and drug discovery platforms. By investigating the biochemical mechanisms that govern stem cell behavior, Plasticell aims to create regenerative small molecule drugs that support tissue development and repair. The company offers comprehensive support for researchers in cell biology by enabling the testing of numerous cell culture variables, thereby optimizing laboratory protocols for various outcomes. This approach facilitates the differentiation of cells and enhances processes such as gene transduction and protein production, ultimately contributing to the advancement of novel therapies in regenerative medicine.

NK:IO is a biotechnology company focused on advancing innovative strategies for natural killer cell-mediated immunotherapy. It specializes in the development of both cell therapies and small molecule therapeutics, with a primary emphasis on cancer treatment. By harnessing the capabilities of natural killer cells, NK:IO aims to enhance the effectiveness of cancer therapies, providing physicians with improved tools to combat the disease. The company's commitment to research and development positions it at the forefront of immunotherapy advancements in the oncology field.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Corryn Biotechnologies is a biotechnology company focused on innovative solutions for chronic wound care. The company has developed the Heals device, which utilizes a contactless approach to enhance the dressing of chronic and complex wounds. Corryn's technology employs applicators that use voltages to extrude fine fibers from various fluids, allowing for the creation of advanced wound dressings. These dressings can be made from both synthetic and natural materials, with the option to include active ingredients. This method enables the deposition of non-woven meshes, contributing to effective tissue repair and improving patient outcomes in wound management.

SMi Systems is a biomedical research and medical equipment manufacturing organization that specializes in developing advanced discovery and diagnostic tools. Its flagship product, SMi Drug Discovery, is a high-performance diagnostic device capable of detecting diseases within the first 24 hours of infection. This innovative device can simultaneously identify multiple diseases and process numerous patient samples in a matter of minutes. By facilitating the detection of individual disease-associated molecules, SMi Systems' automated and high-throughput diagnostic tools enable scientists to measure critical molecular interactions essential for understanding therapeutic mechanisms. This capability allows researchers to observe a vast diversity of molecular interactions across various disease areas and monitor drug binding to their targets, thereby advancing scientific research and clinical diagnostics.

SMi Systems is a biomedical research and medical equipment manufacturing organization that specializes in developing advanced discovery and diagnostic tools. Its flagship product, SMi Drug Discovery, is a high-performance diagnostic device capable of detecting diseases within the first 24 hours of infection. This innovative device can simultaneously identify multiple diseases and process numerous patient samples in a matter of minutes. By facilitating the detection of individual disease-associated molecules, SMi Systems' automated and high-throughput diagnostic tools enable scientists to measure critical molecular interactions essential for understanding therapeutic mechanisms. This capability allows researchers to observe a vast diversity of molecular interactions across various disease areas and monitor drug binding to their targets, thereby advancing scientific research and clinical diagnostics.

Autolomous Ltd is a technology company founded in 2019 and based in Mayfair, United Kingdom, that specializes in developing software solutions for cell and gene therapy manufacturers. Its flagship platform, autoloMATE®, is a cloud-native system that offers comprehensive, end-to-end solutions for advanced therapy manufacturing. The platform facilitates the scheduling of patient cell collections, transportation logistics, and tracking of the manufacturing process to ensure compliance with regulatory requirements. Additionally, autoloMATE® supports the management of electronic batch records, provides insights reporting, and oversees review and release activities. The software is designed to be highly configurable, allowing clients to customize workflows to suit their needs. Autolomous emphasizes compliance with regulatory standards and has achieved multiple ISO certifications in areas such as information security, quality management, and environmental management. By leveraging advanced technology and secure data management practices, Autolomous aims to enhance the availability and affordability of autologous medicines for patients.

CGT Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. Based in central London with over 120 experts and state-of-the-art laboratories, CGT Catapult offers a comprehensive platform for product development, clinical trials, manufacturing, regulatory support, health economics, and market access expertise. Additionally, they are constructing a £55 million large-scale GMP manufacturing centre to accelerate the delivery of cell and gene therapies to patients worldwide.

GG Care helps care residents stay independent and help carers monitor their well-being, comfort, and mood. They serve people with dementia maintain daily routines and stay socially connections shown to reduce cognitive decline and increase happiness and creates an environment to help reduce agitation - significantly reducing the cost of care.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

SyncVR Medical is a leading provider of virtual reality (VR) and augmented reality (AR) solutions for the healthcare sector, operating as the largest XR platform in Europe and the UK. The company offers a comprehensive platform that simplifies the implementation and use of XR technologies across healthcare organizations, supporting over 125 institutions in countries such as the Netherlands, Germany, Denmark, Sweden, Belgium, the UK, and France. SyncVR Medical focuses on enhancing patient care by reducing pain and anxiety, while also improving treatment outcomes through scientifically validated methods. Additionally, the platform facilitates collaboration with more than 25 third-party developers, allowing them to distribute their XR healthcare applications to a broader audience. SyncVR Medical aims to establish itself as the dominant XR platform in the top five European healthcare markets by 2025.

ScubaTx is a company focused on developing an advanced organ preservation system that utilizes the Persufflation method, a well-established technique aimed at enhancing organ transportation. By leveraging innovative software design, ScubaTx aims to provide significant cost savings for healthcare providers, thereby facilitating an expanded supply of viable organs for transplantation. The company’s technology is designed to protect and improve the condition of grafts during the preservation process, ultimately empowering clinicians worldwide to increase the availability of life-saving organs.

Lindus Health is a clinical research organization that specializes in managing end-to-end clinical trials for healthcare and biotechnology companies. The company offers services such as ethics and IRB submissions, trial monitoring, data management, biostatistics, regulatory affairs, and payor relations. Lindus Health employs an in-house team of clinicians and researchers to accelerate the clinical trial process using its proprietary software platform, Curebase OS, which automates workflows and reduces manual inefficiencies. The company also leverages real-world patient data for precise participant recruitment and smarter trial design, aiming to make clinical trials faster and more cost-effective while improving patient treatment outcomes.

Maxion Therapeutics is a biopharmaceutical company focused on developing innovative therapies for diseases driven by ion channels and G protein-coupled receptors (GPCRs). The company utilizes a unique drug discovery platform that integrates ion channel-modulating mini-proteins, known as knottins, derived from venom and other natural sources. By combining these knottins with antibody frameworks, Maxion aims to create long-acting, safe, and effective therapeutics that address previously inaccessible medical targets. This approach enables the potential treatment of various conditions, including chronic pain, autoimmune disorders, and heart disease, ultimately enhancing patient care through advanced drug development.

Nanovery Limited, based in London, United Kingdom, specializes in the development of nanorobots aimed at detecting cancer mutations. Incorporated in 2018, the company leverages advances in nanotechnology, medicinal chemistry, and artificial intelligence to create a platform that enables rapid and sensitive identification of challenging disease biomarkers. These nanorobots are designed to be introduced into blood samples, where they capture circulating tumor DNA and emit a fluorescent signal, facilitating point-of-care detection. This innovative approach not only aids in the early detection of cancer but also enhances the ability to predict the evolution of cancer cells, significantly improving the chances of patient survival. Supported by academic experts, clinicians, and industry leaders, Nanovery is committed to making cancer detection more efficient and accessible.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to enhance life expectancy for patients suffering from glioblastoma, a brain tumor known for its poor prognosis and limited treatment options. Recognizing the significant gaps in effective therapies, co-founder Dr. Richard Fu, an academic neurosurgeon, teamed up with biomedical engineer Dr. Chris Bullock to address design flaws in existing electric field therapies. Their solution leverages advanced materials science, including the use of graphene, to optimize device performance and patient outcomes. Since its inception, QV Bioelectronics has garnered nearly $1 million in funding from various UK institutions and over $1 million from international life science investors. The company operates from its research hub in Alderley Park, Cheshire, and boasts a multidisciplinary team with extensive experience in bringing innovative medical devices to the clinic.

GenoME Diagnostics is a biotechnology company focused on developing innovative blood tests aimed at improving cancer detection and diagnosis. The company has created the OvaME product, which enhances the traditional CA125 blood tests, offering a more accurate and earlier detection of various cancers. By employing advanced techniques, GenoME Diagnostics aims to minimize misdiagnosis and late detection, enabling healthcare professionals to diagnose and treat patients more effectively. This commitment to developing life-saving diagnostic tools positions the company as a significant player in the field of oncology diagnostics.

Doctoria is a virtual healthcare platform to enable doctors and patients to connect better.

LightOx is a biotechnology company focused on developing innovative molecular tools and light-activated therapeutics for cancer treatment. The company offers a unique range of fluorescent probes that are smaller than existing commercial options, allowing for versatile use in imaging, therapeutics, and assay development. These probes can function as freely-moving agents within cells or be coupled with flexible linkers to provide specificity for various research applications. LightOx is dedicated to improving patient outcomes by creating targeted drug compounds that selectively eliminate tumor cells while minimizing damage to surrounding healthy tissues. This approach aims to enhance the efficiency of cancer treatment and contribute to better long-term health for patients.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

EnsiliTech is a biopharmaceuticals company focused on preserving the integrity of vaccines and other biological materials. The company has developed a novel ensilication technology that utilizes protective silica nanoshells to shield vaccine components from environmental degradation. This innovative approach aims to prevent vaccine spoilage, thereby enhancing the shelf-life of these critical biological products. By improving the stability and accessibility of vaccines, EnsiliTech seeks to reduce waste and contribute to global vaccination efforts, ensuring that more people can benefit from life-saving immunizations.

EnsiliTech is a biopharmaceuticals company focused on preserving the integrity of vaccines and other biological materials. The company has developed a novel ensilication technology that utilizes protective silica nanoshells to shield vaccine components from environmental degradation. This innovative approach aims to prevent vaccine spoilage, thereby enhancing the shelf-life of these critical biological products. By improving the stability and accessibility of vaccines, EnsiliTech seeks to reduce waste and contribute to global vaccination efforts, ensuring that more people can benefit from life-saving immunizations.

Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Healthera's technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.

Amber Therapeutics is a biotechnology company that specializes in developing advanced bioelectrical therapies aimed at treating functional disorders of the peripheral nervous system. The company creates a bioelectronic platform that delivers closed-loop bioelectrical treatments, which can sense and adapt to the patient's needs while also providing stimulation. By focusing on conditions such as mixed urinary incontinence, Amber Therapeutics seeks to enhance clinical efficacy and patient outcomes through innovative approaches that emphasize the peripheral nervous system rather than the central nervous system. Its technology has the potential to significantly improve treatment methods and overall patient care in targeted disease areas.

The National Biofilms Innovation Centre (NBIC) serves as a collaborative hub uniting academia, industry, government, and public policy to address the challenges posed by biofilms, which significantly impact global economic activity across sectors such as food, health, shipping, clean water, and energy. Supported by funding from the BBSRC, Innovate UK, and Hartree Centre, NBIC's mission focuses on fostering a network for research and innovation that catalyzes partnerships with industry to drive breakthrough innovations. The Centre facilitates the exploration of unmet needs and the exchange of ideas through various initiatives, including roadmaps, workshops, and conferences. Additionally, NBIC is dedicated to nurturing the next generation of scientists through PhD and Post-Doc programs, alongside entrepreneurial training, aimed at enhancing their expertise and understanding of the commercial landscape while promoting the creation of new start-ups.

The Medicines Discovery Catapult is the centre of national expertise for the discovery of medicines.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

Drill Surgeries is a company dedicated to enhancing the outcomes of trauma and orthopedic surgeries through its innovative AI-powered navigation system. This technology aims to significantly reduce the failure rate of surgeries from 36% to less than 4% by providing real-time guidance during osteosynthesis procedures. By employing proprietary AI algorithms and mixed reality technologies, Drill Surgeries facilitates a remarkable 83% reduction in operating room time. Additionally, the company’s solutions eliminate the need for unnecessary X-rays, leading to substantial cost savings of approximately $2,000 per operation for hospitals. Through these advancements, Drill Surgeries empowers doctors to perform complex procedures more efficiently and effectively, ultimately improving patient care and operational efficiency in healthcare settings.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

AMPLY Discovery is a biotechnology company focused on drug discovery, utilizing machine learning and synthetic biology to explore vast biological datasets for novel drug and nutraceutical candidates. The company operates a proprietary platform that integrates in silico and in vitro approaches to identify first-in-class molecules, addressing significant health challenges such as cancer, metabolic diseases, and multidrug-resistant infections. By digitizing life's natural diversity, AMPLY enhances the predictability and cost-effectiveness of discovering new therapeutics, enabling research entities to identify promising drug candidates based on their functional properties.

aTen Therapeutics is a biotechnology company focused on developing innovative therapeutic antibodies aimed at treating major diseases, particularly cancer. The company employs novel antibody approaches to target crucial control pathways that play a significant role in cancer cell growth, invasion, and metastasis. By utilizing anti-cancer agents, aTen Therapeutics' products have the potential to inhibit cancer cell proliferation and improve treatment outcomes for patients. Their commitment to advancing biopharmaceutical solutions reflects a goal of enhancing the quality of life for individuals affected by cancer and preventing the progression of the disease. With a management team experienced in the biopharmaceutical industry, aTen Therapeutics is well-positioned to contribute to the development of effective therapies that can significantly impact patient care.

Nolea Health is a specialized jobs marketplace platform focused on mental healthcare, aiming to alleviate the staffing shortages in the sector. The company utilizes an AI-driven platform to efficiently match verified mental health professionals with available positions in healthcare organizations. By streamlining the onboarding and credentialing processes, Nolea Health minimizes logistical challenges that often hinder recruitment efforts, thereby enhancing the efficiency of hiring. The platform prioritizes flexibility for clinicians, allowing them to align their work preferences with the needs of healthcare providers based on location, license type, specialty, and availability. This approach not only addresses the supply-demand mismatch in mental health services but also promotes job satisfaction and improves the overall effectiveness of clinical care.

BoobyBiome is a company focused on enhancing infant health through the development of probiotic supplements specifically designed for babies with compromised microbiomes. By leveraging specialized expertise and research, BoobyBiome aims to recreate the beneficial bacteria associated with breast milk, particularly for infants born prematurely or those who rely on formula feeding. Their products are formulated to closely mimic the properties of breast milk, providing essential support for gut health and immune system development in infants. Through these innovative probiotic solutions, BoobyBiome seeks to promote healthy growth and development during a critical stage of life.

BoobyBiome is a company focused on enhancing infant health through the development of probiotic supplements specifically designed for babies with compromised microbiomes. By leveraging specialized expertise and research, BoobyBiome aims to recreate the beneficial bacteria associated with breast milk, particularly for infants born prematurely or those who rely on formula feeding. Their products are formulated to closely mimic the properties of breast milk, providing essential support for gut health and immune system development in infants. Through these innovative probiotic solutions, BoobyBiome seeks to promote healthy growth and development during a critical stage of life.

Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative tools and technologies for drug screening and safety testing. Established in 2016, the company offers a range of products including induced pluripotent stem cells, primary human and multispecies cells, and a comprehensive cell culture and analysis package. Stemnovate employs advanced devices such as micro physiological systems and microfluidic technologies to facilitate research and development. One of its notable projects, the "Liver on chip," focuses on liver toxicity testing and integrates cellular reprogramming, stem cell research, and organ-on-chip technology. The company also provides services in cell reprogramming, differentiation, and application development, catering to a diverse clientele that includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions.

Eleven Therapeutics is a biotechnology company leveraging artificial intelligence to advance medicinal nucleic acids, particularly focusing on RNAi therapies and mRNA therapeutics. The company employs AI-driven parallel functional testing and combinatorial chemistry to develop programmable molecules called SCSI-RNAs, which can target specific diseases or biological targets. Additionally, Eleven Therapeutics is pioneering extended durability mRNA therapeutics designed to address unmet medical needs in metabolic, endocrinologic, and infectious diseases. Their proprietary high-throughput AI-enabled screening platforms enhance the stability and targeted delivery of these nucleic acid molecules, ensuring superior durability and specificity.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Neumind is a healthcare technology company established in 2019, headquartered in Great Shelford, Cambridge. It develops smartphone-based solutions to assist individuals living with neurological conditions or injuries, promoting independence and functionality. The company's flagship product, Alfred, offers practical support and therapeutic interventions rooted in neurorehabilitation and cognitive-behavioral science. Alfred uses smartphone technology to enhance key cognitive functions and stimulate neural pathways, benefiting both users and their caregivers.

NRG Therapeutics is a drug discovery company established in 2018, specializing in therapeutic solutions aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and motor neuron disease. Founded by a team of professionals with extensive experience in the biotech and pharmaceutical sectors, the company focuses on developing brain-penetrant mitochondrial permeability transition pore inhibitors specifically for Parkinson's disease. NRG Therapeutics seeks to create innovative medicines that preserve mitochondrial function, thereby enabling effective treatment options for patients suffering from chronic neurodegenerative disorders.

BoobyBiome is a company focused on enhancing infant health through the development of probiotic supplements specifically designed for babies with compromised microbiomes. By leveraging specialized expertise and research, BoobyBiome aims to recreate the beneficial bacteria associated with breast milk, particularly for infants born prematurely or those who rely on formula feeding. Their products are formulated to closely mimic the properties of breast milk, providing essential support for gut health and immune system development in infants. Through these innovative probiotic solutions, BoobyBiome seeks to promote healthy growth and development during a critical stage of life.

We already know that upto 50% of patients struggle to take their medicines – patients are not well-supported and too often it remains a hidden problem until it's too late. CONNECT Care want to change that: empowering patients and, at the same time, using data-driven insights to enable clinicians and carers to provide better support in real-time.

Kynos Therapeutics is a biotechnology company focused on developing KMO inhibitors to address unmet medical needs in inflammation, immunity, and metabolism. By targeting the Kaiser-Meyer-Olkin (KMO) enzyme, the company aims to regulate systemic inflammation and tackle the underlying pathology of various medical conditions. Kynos Therapeutics is dedicated to providing innovative therapies that represent a new generation of potent KMO inhibitors, offering potential solutions in areas where current treatment options are limited.

Medwise.ai operates a customizable search platform designed to enhance clinical decision support for doctors. Leveraging natural language processing and artificial intelligence, the platform allows healthcare professionals to efficiently search for and organize medical knowledge. By utilizing real-world data, Medwise.ai provides valuable insights and intelligence to various stakeholders within the healthcare ecosystem. This innovative approach not only extends the capabilities of physicians but also aims to improve patient care and outcomes.

GenoME Diagnostics is a biotechnology company focused on developing innovative blood tests aimed at improving cancer detection and diagnosis. The company has created the OvaME product, which enhances the traditional CA125 blood tests, offering a more accurate and earlier detection of various cancers. By employing advanced techniques, GenoME Diagnostics aims to minimize misdiagnosis and late detection, enabling healthcare professionals to diagnose and treat patients more effectively. This commitment to developing life-saving diagnostic tools positions the company as a significant player in the field of oncology diagnostics.

Five Alarm Bio is a drug discovery company based in Cambridge, United Kingdom, founded in 2016. The company specializes in researching and developing anti-aging therapies aimed at reducing age-related illnesses and limitations. Five Alarm Bio employs a small molecule strategy to enhance the body's defenses against damage that accumulates with aging, with the goal of extending the lifespan of healthy cells and mitigating the development and progression of diseases associated with aging.

Eleven Therapeutics is a biotechnology company leveraging artificial intelligence to advance medicinal nucleic acids, particularly focusing on RNAi therapies and mRNA therapeutics. The company employs AI-driven parallel functional testing and combinatorial chemistry to develop programmable molecules called SCSI-RNAs, which can target specific diseases or biological targets. Additionally, Eleven Therapeutics is pioneering extended durability mRNA therapeutics designed to address unmet medical needs in metabolic, endocrinologic, and infectious diseases. Their proprietary high-throughput AI-enabled screening platforms enhance the stability and targeted delivery of these nucleic acid molecules, ensuring superior durability and specificity.

Sixfold Bioscience Inc. is a London-based company founded in 2018 that specializes in the development of innovative drug delivery techniques aimed at treating cancer patients. The company focuses on engineering programmable oligonucleotide delivery systems that are designed to deliver RNA specifically to diseased cells. This targeted approach enhances the efficacy of treatments while minimizing side effects, positioning Sixfold Bioscience at the forefront of advancements in cancer therapy.

We already know that upto 50% of patients struggle to take their medicines – patients are not well-supported and too often it remains a hidden problem until it's too late. CONNECT Care want to change that: empowering patients and, at the same time, using data-driven insights to enable clinicians and carers to provide better support in real-time.